Cerus (CERS) vs Senseonics (SENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cerus (CERS) has outperformed Senseonics (SENS) over the past year, gaining 43.1% versus a loss of 2.3%. Over five years, CERS leads with a -62.6% price change compared with -86.1% for SENS. Senseonics is the larger company by market cap ($484.3 million vs $461.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CERS | SENS |
|---|---|---|
| Share price | $2.29 | $9.16 |
| Market cap | $461.49M | $484.33M |
| 1-day change | -2.14% | -8.03% |
| YTD return | +11.17% | +65.94% |
| 1-year return | +43.13% | -2.35% |
| 5-year return | -62.58% | -86.12% |
| EPS (TTM) | $-0.03 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.47 | $10.64 |
| 52-week low | $1.38 | $4.79 |
| Distance from 52-week high | -34.01% | -13.91% |
| Analyst consensus | none | buy |
| Avg. price target upside | +124.02% | +47.38% |
| Average volume | 2.15M | 675.79K |
| Shares outstanding | 201.52M | 52.87M |
| Employees | 261 | 130 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CERS has outperformed SENS by 45.5 percentage points over the past year.
About Cerus
CERS stock →Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Healthcare · Medical Devices · 261 employees
About Senseonics
SENS stock →Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
Healthcare · Medical Devices · 130 employees
CERS vs SENS FAQ
Which is bigger, Cerus or Senseonics?
Senseonics (SENS) is larger, with a market capitalization of $484.33M compared with $461.49M for Cerus (CERS).
Which stock has performed better over the past year, CERS or SENS?
CERS returned +43.13% over the past 12 months, compared with -2.35% for SENS (price return, excluding dividends). Past performance does not predict future results.
Are Cerus and Senseonics in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.